MedPath

Embolization in Splenic Trauma

Not Applicable
Completed
Conditions
Trauma to the Spleen
Interventions
Device: Splenic artery embolization with vascular embolic coils
Device: Splenic artery embolization with vascular embolic plugs
Registration Number
NCT03613454
Lead Sponsor
University of Alabama at Birmingham
Brief Summary

Randomized, prospective, feasibility study to begin evaluating the efficacy, safety, and cost of using either coils or vascular plugs (VPs) for proximal splenic artery embolization in the setting of traumatic splenic injury.

Detailed Description

Splenic preservation rates are improved for participants with high-grade splenic injuries (defined as Grade III-V injuries by the American Association for the Surgery of Trauma (AAST) guidelines) when non-operative management is supplemented by image-guided, trans-catheter splenic artery embolization (SAE). SAE is currently the standard of care for hemodynamically stable participants with high-grade splenic injuries. In proximal SAE (pSAE), the mid-splenic artery is embolized between the origins of the dorsal pancreatic artery and pancreatica magna artery with either VPs or coils. This reduces the intra-splenic arterial pressure which allows the parenchyma time to heal. Splenic perfusion is maintained via a collateral pathway consisting of flow from the splenic artery proximal to the site of embolization through the smaller dorsal pancreatic artery to the transverse pancreatic artery to the pancreatica magna artery which then delivers a slower, smaller amount of blood to the splenic artery distal to the site of embolization. Additionally, collateral supply from the short gastric and gastroepiploic arteries helps to protect the spleen from infarction and/or abscess formation.

pSAE is most often accomplished using either coils or VPs as the embolic agent, both of which are FDA-approved and clinically-available. Coils have a long history of efficacy and safety for embolization and are thus familiar embolic agents to most endovascular specialists. Further, coils large enough to embolize the mid-splenic artery can be deployed through a standard micro-catheter, which means they can be used in even the most tortuous splenic arteries. However, multiple coils may need to be deployed in the same patient to achieve hemostasis in the mid-splenic artery that may increase their overall cost, iodinated contrast use, procedural time, and the radiation exposure to the participant and medical staff. Additionally, given the high-flow nature of the splenic artery, even an appropriately sized coil may migrate distally. A typical pSAE using coils will involve the deployment of one helical coil followed by multiple packing coils until hemostasis is achieved. VPs attempt to overcome the limitations of coils. For example, the deployment of a single VP can typically provide hemostasis in the mid-splenic artery which theoretically reduces procedural time, contrast load, and radiation exposure. Despite this, VPs are more expensive than coils on a per unit basis and are usually less familiar devices to endovascular specialists. Another drawback of VPs is that they cannot be deployed through a standard micro-catheter but rather require the advancement of a larger, stiffer 0.035 inch system into the mid-splenic artery. This may limit their use in very tortuous splenic arteries. Currently, the selection of embolic agent for pSAE is primarily based on operator experience and preference. The embolic efficacy, technical success, and cost of using coils compared to VPs has been evaluated in other diseases; yet, to the best of our knowledge, these embolic agents have never been compared for their use in pSAE, much less in a randomized, prospective fashion.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
48
Inclusion Criteria
  • Patients presenting to the University of Alabama at Birmingham (UAB) emergency room requiring embolization of the splenic artery
Read More
Exclusion Criteria

Not provided

Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Splenic artery embolization with vascular embolic coilsSplenic artery embolization with vascular embolic coils-
Splenic artery embolization with vascular embolic plugsSplenic artery embolization with vascular embolic plugs-
Primary Outcome Measures
NameTimeMethod
Number of Participants Who Were Enrolled Within 18 Months of Study InitiationThrough study completion, an average of 1 year

The primary outcome of the study will be enrolling 50 participants in the study within 18 months of study initiation with adequate 30 day follow-up on all participants.

Secondary Outcome Measures
NameTimeMethod
Number of Participants With Embolization SuccessThrough study completion, an average of 1 year

This outcome will be measured by the ability of the operator to deploy the required embolic with resultant stasis in the splenic artery. This will be compared between the two groups.

Number of Participants With Immediate ComplicationsDuring the embolization procedure, an average of 1 hour

This outcome will be measured by the number of intra-procedural complications and compared between the two groups

Number of Participants With Splenic Salvage30 days after procedure

This outcome will be measured by splenic salvage rate at 30 days and compared between groups. Splenic salvage was defined as the absence of splenectomy in the medical record or per patient report.

Radiation ExposureDuring the embolization procedure, an average of 1 hour

The radiation exposure during the embolization procedure for each embolic will be measured and compared.

Contrast VolumeDuring the embolization procedure, an average of 1 hour

The amount of contrast used during the procedure will be measured for each group and compared.

Trial Locations

Locations (1)

April Riddle

🇺🇸

Harpersville, Alabama, United States

© Copyright 2025. All Rights Reserved by MedPath